Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Compare Drugs in Interleukin-23 Antagonist [EPC]

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

Drug	Reports	Deaths	Death Rate	Hosp.	Life-Threat.	Avg Age	% Female
USTEKINUMAB	85,332	4,519	5.3%	17,127	4,352	48.1 yrs	60.3%
GUSELKUMAB	27,987	364	1.3%	2,031	154	52.6 yrs	57.6%
RISANKIZUMAB	2,642	41	1.6%	439	23	52.1 yrs	51.3%
TILDRAKIZUMAB	869	89	10.2%	389	39	57.9 yrs	42.5%
MIRIKIZUMAB	41	3	7.3%	13	3	50.1 yrs	47.5%

Head-to-Head Comparisons

USTEKINUMAB vs GUSELKUMAB USTEKINUMAB vs RISANKIZUMAB USTEKINUMAB vs TILDRAKIZUMAB USTEKINUMAB vs MIRIKIZUMAB GUSELKUMAB vs RISANKIZUMAB GUSELKUMAB vs TILDRAKIZUMAB GUSELKUMAB vs MIRIKIZUMAB RISANKIZUMAB vs TILDRAKIZUMAB RISANKIZUMAB vs MIRIKIZUMAB TILDRAKIZUMAB vs MIRIKIZUMAB

← Back to Interleukin-23 Antagonist [EPC] Class side effects →